Parathyroid hormone 100micrograms/71.4microlitre dose powder and solvent for solution for injection cartridges
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Parathyroid hormone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Parathyroid hormone on the MHRA register
Natpar 100micrograms/dose powder and solvent for solution for injection cartridges
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Parathyroid hormone
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(11)
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625)
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
Thoracoscopic excision of mediastinal parathyroid tumours (HTG159)
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)
Minimally invasive video‑assisted parathyroidectomy (HTG350)
Chronic kidney disease: assessment and management (NG203)
Thyroid cancer: assessment and management (NG230)
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)
Difelikefalin for treating pruritus in people having haemodialysis (TA890)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1.5 hours
Mechanism
The biological actions of rhPTH are mediated through binding to at least two dis…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
55%
Half-life
1.5 hours
Volume of distribution
40%
Metabolism
30%
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 215 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
It may play a significant role in pancreatic function. PTH2R presence in neurons indicates that it may function as a neurotransmitter receptor (By similarity)
PMID:10913300 PMID:18375760 PMID:19674967 PMID:27160269 PMID:30975883 PMID:35932760 PMID:8397094
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) .
PMID:30975883 PMID:35932760
PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity .
PMID:20172855 PMID:30975883 PMID:35932760
PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH PMID:35932760
ATC H05AA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Parathyroid hormone
Additional database identifiers
Drugs Product Database (DPD)
5252
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9609
GeneCards
PTH2R
Guide to Pharmacology
332
UniProt Accession
PTH2R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9608
GenAtlas
PTHR1
GeneCards
PTH1R
GenBank Gene Database
BC112247
Guide to Pharmacology
331
UniProt Accession
PTH1R_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: